CHEST 2021, News
Researchers conducted pooled analysis of the COUGH-1 and COUGH-2 phase 3 trials of gefapixant for treating refractory/unexplained chronic cough.
The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.
ESMO 2021, News
Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.
ATS 2021, News
Twice daily gefapixant 45 mg was associated with a clinically meaningful reduction in cough frequency in patients with chronic cough.
Expert recommendations for the diagnosis and management of gastroesophageal reflux disease (GERD).
Drugs in the Pipeline
The NDA submission is based on data from the double-blind, placebo-controlled phase 3 studies, COUGH-1 and COUGH-2.
Types of urinary incontinence and its potential causes.
Women with chronic cough in the United States and United Kingdom were more likely to have a higher number of cough triggers.
Drugs in the Pipeline, News
The double-blind, placebo-controlled studies, COUGH-1 and COUGH-2, included 730 and 1314 adult patients with refractory or unexplained chronic cough for at least 1 year, respectively.
BAY 1817080, a potent selective P2X3 receptor antagonist, may have utility as a new treatment for refractory chronic cough.